BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8745670)

  • 1. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study.
    Bonneterre J; Hecquet B
    Bull Cancer; 1995 Dec; 82(12):1038-43. PubMed ID: 8745670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
    Park JO; Rha SY; Yoo NC; Kim JH; Roh JK; Min JS; Kim BS; Chung HC
    Am J Clin Oncol; 1997 Dec; 20(6):569-72. PubMed ID: 9391542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
    Huc P; Block S; Carlier D; Darloy F; Bonneterre ME; Bleuse JP; Fournier C; Bonneterre J
    Bull Cancer; 1998 Jun; 85(6):562-8. PubMed ID: 9752283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial.
    Gebbia V; Cannata G; Testa A; Curto G; Valenza R; Cipolla C; Latteri MA; Gebbia N
    Cancer; 1994 Oct; 74(7):1945-52. PubMed ID: 8082100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. Italian Group for Antiemetic Research.
    J Clin Oncol; 1995 Sep; 13(9):2417-26. PubMed ID: 7666102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients.
    Stewart A; McQuade B; Cronje JD; Goedhals L; Gudgeon A; Corette L; Froger X; Tubiana-Hulin M; Laplaige P; Roberts JT
    Oncology; 1995; 52(3):202-10. PubMed ID: 7715904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
    Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
    J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers.
    Farley PA; Dempsey CL; Shillington AA; Kulis-Robitaille C; Colgan K; Bernstein G
    Am J Health Syst Pharm; 1997 Nov; 54(21):2478-82. PubMed ID: 9359954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
    Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
    Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.
    Italian Group for Antiemetic Research
    N Engl J Med; 1995 Jan; 332(1):1-5. PubMed ID: 7990859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
    Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
    Kaizer L; Warr D; Hoskins P; Latreille J; Lofters W; Yau J; Palmer M; Zee B; Levy M; Pater J
    J Clin Oncol; 1994 May; 12(5):1050-7. PubMed ID: 8164029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.
    Martoni A; Angelelli B; Guaraldi M; Strocchi E; Pannuti F
    Eur J Cancer; 1996 Jan; 32A(1):82-5. PubMed ID: 8695248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
    Kalaycio M; Mendez Z; Pohlman B; Overmoyer B; Boparai N; Jones E; Bolwell B
    J Cancer Res Clin Oncol; 1998; 124(5):265-9. PubMed ID: 9645457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
    Navari R; Gandara D; Hesketh P; Hall S; Mailliard J; Ritter H; Friedman C; Fitts D
    J Clin Oncol; 1995 May; 13(5):1242-8. PubMed ID: 7738628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.